can tirzepatide cause low libido Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it Are Sexual Side Effects Emerging

Another paper found that people with a genetic tendency toward low dopamine levels may face higher risk of depression and suicidal thoughts on these medications

Double the dose from an identical syringe reading

Despite the runaway commercial success of injectables semaglutide and tirzepatide, and a projected global opportunity for obesity pharmacotherapies worth $131Bn by 2028 [2], a number of important issues must be addressed for anti-obesity medicines to fulfil their tremendous potential as public health interventions: Ensuring affordability by patients, in out-of-pocket markets, and by health systems to expand reimbursement of weight loss medicines to ensure equity of access and enable the broad adoption of therapies in eligible patient populations Securing adequate product supply that meets fast growing demand Maintaining weight loss and realising associated, long-term health benefits, e.g., improvements in cardio-metabolic risk factors and co-morbidities Oral obesity treatments will play a critical role in overcoming these challenges, for example, as convenient, long-term maintenance therapy following time-limited induction therapy with injectables

GLP-1 medications are not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)